Resource Center

Use this page to quickly find guides, study summaries, and topic collections tied to GLP-1 and NAION questions.

Featured guides, explainers, article collections, and FAQ-style help
Open the article archive when you want broader reading
Choose a guide, open the archive, or contact the team

Browse featured guides Blog

Browse by collection

Start with the three most-used collections

Each collection is designed for a specific reading goal so you can move faster and skip irrelevant pages.

Featured guide paths

Featured

Guides, explainers, and practical help should feel like one clear library.

Start here for high-priority guides and plain-language explainers before deeper reading.

Topic collections

Featured

Browse topic collections without losing the main site path.

Use this group when you need drug pages, study summaries, and safety context together.

Latest public references

Recent court and FDA references

Read these internal summaries first, then decide whether you need deeper source details.

Official court source

2026-01-26

MDL 3163 court page

The Eastern District of Pennsylvania keeps the official MDL 3163 page, conference access, orders, and related public court materials in one place.

Read MDL 3163 summary

Official docket report

2026-04-01

JPML monthly pending MDL report

The April 1, 2026 JPML pending report lists MDL 3163 with 73 pending actions and keeps the GLP-1 / NAION litigation inside the national pending-MDL…

Read JPML summary

Official FDA source

2026-03-03

FDA warning letters on compounded GLP-1 marketing

FDA announced 30 warning letters addressing false or misleading telehealth marketing of compounded GLP-1 products and clarified that compounded drugs are not FDA-approved.

Read FDA summary